(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
08 December 2022 (08.12.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/253167 A8

(51) International Patent Classification:
C07D 471/04 (2006.01) *A61P 35/00* (2006.01)
C07D 487/04 (2006.01)

(21) International Application Number:
PCT/CN2022/095901

(22) International Filing Date:
30 May 2022 (30.05.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PCT/CN2021/097679
01 June 2021 (01.06.2021) CN
PCT/CN2022/085680
08 April 2022 (08.04.2022) CN

(71) Applicant: **JANSSEN PHARMACEUTICA NV** [BE/BE]; Turnhoutseweg 30, 2340 Beerse (BE).

(71) Applicant *(for SC only)*: **JOHNSON & JOHNSON (CHINA) INVESTMENT LTD.** [CN/CN]; 2101, No.1 Building, 65 Gui Qing Road, Xuhui District, Shanghai 200233 (CN).

(72) Inventors: **CAI, Wei**; Johnson & Johnson (China) Investment Ltd., 2101, No.1 Building, 65 Gui Qing Road, Xuhui District, Shanghai 200233 (CN). **THURING, Johannes Wilhelmus J.**; Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse (BE). **HULPIA, Fabian**; Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse (BE). **DAI, Xuedong**; Johnson & Johnson (China) Investment Ltd., 2101, No.1 Building, 65 Gui Qing Road, Xuhui District, Shanghai 200233 (CN). **LI, Ming**; Johnson & Johnson (China) Investment Ltd., 2101, No.1 Building, 65 Gui Qing Road, Xuhui District, Shanghai 200233 (CN). **DENG, Xiangjun**; Johnson & Johnson (China) Investment Ltd., 2101, No.1 Building, 65 Gui Qing Road, Xuhui District, Shanghai 200233 (CN). **LIANG, Chao**; Johnson & Johnson (China) Investment Ltd., 2101, No.1 Building, 65 Gui Qing Road, Xuhui District, Shanghai 200233 (CN). **NG, Alicia Tee Fuay**; Johnson & Johnson (China) Investment Ltd., 2101, No.1 Building, 65 Gui Qing Road, Xuhui District, Shanghai 200233 (CN). **SUN, Zhen**; Johnson & Johnson (China) Investment Ltd., 2101, No.1 Building, 65 Gui Qing Road, Xuhui District, Shanghai

(54) Title: SUBSTITUTED PHENYL-1H-PYRROLO[2, 3-c]PYRIDINE DERIVATIVES




FIGURE 1

(57) Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, including but not limited to leukemia, myelodysplastic syndrome (MDS), and myeloproliferative neoplasms (MPN); and diabetes.

WO 2022/253167 A8

[Continued on next page]

200233 (CN). **ZHANG, Zhigao**; Johnson & Johnson (China) Investment Ltd., 2101, No.1 Building, 65 Gui Qing Road, Xuhui District, Shanghai 200233 (CN). **DEMIN, Samuël Dominique**; Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse (BE). **DYUBANKOVA, Natalia Nikolaevna**; Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse (BE). **JOUFFROY, Matthieu, Dominique**; Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse (BE). **LEPRI, Susan**; Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse (BE). **DARVILLE, Nicolas Freddy Jacques Bruno**; Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse (BE). **PANDE, Vineet**; Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse (BE). **SCHEPENS, Wim Bert Griet**; Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse (BE). **EDWARDS, James Patrick**; Janssen Research & Development, LLC, 920 US Route 202, PO Box 300, Raritan, New Jersey 08869 (US). **QUEROLLE, Olivier Alexis Georges**; Janssen-Cilag, 1 Rue Camille Desmoulins, TSA 91003, 92787 Issy-les Moulineaux Cedex 9 (FR).

(74) **Agent: NTD UNIVATION INTELLECTUAL PROPERTY AGENCY LTD.**; 10th Floor, Tower C, Beijing Global Trade Center, 36 North Third Ring Road East, Dongcheng District, Beijing 100013 (CN).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

(48) **Date of publication of this corrected version:**
09 March 2023 (09.03.2023)

(15) **Information about Correction:**
see Notice of 09 March 2023 (09.03.2023)